Sign Out
Click on icon to see table/diagram/imageImmune system disorders: Very rare: Hypersensitivity reactions (urticaria, exanthema).
Gastrointestinal disorders: Very rare: In clinical studies with benfotiamine, gastrointestinal disorders like nausea and other gastrointestinal complaints were documented in single cases. However, the frequency did not differ significantly from placebo treated groups. A causal relationship to benfotiamine is not clearly established and may be dose dependent.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
View ADR Reporting Link
Continue with Google